ImClone Systems Incorporated

Contact
imclone.com
+12126451405

ImClone Systems Incorporated

180 Varick Street
10014 New York City
USA
+12126451405
imclone.com
Contact
Profile Products News
Contact

About ImClone Systems Incorporated

ImClone Systems is a fully integrated global biopharmaceutical company committed to advancing oncology care by developing and commercializing a portfolio of targeted biologic treatments designed to address the medical needs of patients with a variety of cancers.

On November 24, 2008, ImClone Systems became a wholly-owned subsidiary of Eli Lilly and Company (NYSE: LLY).

Read more about ImClone Systems Incorporated
Facts about ImClone Systems Incorporated
  • Focus : Manufacturer
  • Industry : Pharma

Product portfolio of ImClone Systems Incorporated

Product portfolio

Show all

News about ImClone Systems Incorporated

ImClone Systems Incorporated

04-Sep-2009 | business & finance

DxS Enters Into Collaboration With Bristol-Myers Squibb And ImClone Systems To Provide a K-RAS Companion Diagnostic For ERBITUX

DxS has entered into a collaboration agreement with Bristol-Myers Squibb Company and ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company, ...

Read news
ImClone Systems Incorporated

26-Nov-2008 | business & finance

Lilly Completes Cash Tender Offer for ImClone Systems

Eli Lilly and Company and ImClone Systems Incorporated announced the successful completion of the previously announced tender offer by Lilly's wholly-owned ...

Read news
ImClone Systems Incorporated

12-Nov-2007 | business & finance

Dyax Corp. Announces Extension of Antibody Library Collaboration with ImClone Systems

Dyax Corp. announced the extension of the antibody library collaboration with ImClone Systems Incorporated for the discovery of therapeutic antibodies. ...

Read news
ImClone Systems Incorporated

19-Oct-2007 | business & finance

Merck Announces Joint Agreement With ImClone and Bristol-Myers Squibb for Erbitux in Japan

Co-development and co-commercialization of Erbitux in metastatic colorectal cancer upon health authority approval

Read news
ImClone Systems Incorporated

08-Feb-2007 | research and development

UCB gains global rights pertaining to VEGFR-2 for CDP-791

UCB announced that UCB and ImClone Systems Incorporated have agreed to terminate their CDP-791 development agreement. UCB will enjoy freedom to operate ...

Read news
ImClone Systems Incorporated

18-Aug-2005 | business & finance

UCB and Imclone Systems enter into worldwide partnership for CDP-791 therapy targeting the development of tumor vasculature

UCB and ImClone Systems Incorporated announced that they have entered into a worldwide strategic partnership for the development and commercialization of ...

Read news
Show more news about ImClone Systems Incorporated

Here you will find ImClone Systems Incorporated